Workflow
梅花生物(600873) - 2022 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2022 was RMB 6,712,290,632.48, representing a 26.45% increase compared to RMB 5,308,348,754.19 in the same period last year[4]. - Net profit attributable to shareholders reached RMB 1,158,775,246.72, a significant increase of 183.71% from RMB 408,441,231.32 year-on-year[4]. - The net profit after deducting non-recurring gains and losses was RMB 1,136,042,840.95, up 193.39% from RMB 387,215,033.23 in the previous year[4]. - The net cash flow from operating activities improved to RMB 728,205,947.13, a 308.75% increase from a negative RMB 348,842,872.03 in the same period last year[4]. - Basic and diluted earnings per share were both RMB 0.37, reflecting a 184.62% increase compared to RMB 0.13 in the previous year[4]. - The weighted average return on equity rose to 10.35%, up from 4.4% in the same period last year, marking a 5.95% increase[4]. - The gross profit margin improved from 16.47% to 26.24%, contributing to the significant increase in net profit[7]. - Total revenue for Q1 2022 reached ¥6,712,290,632.48, an increase of 26.4% compared to ¥5,308,348,754.19 in Q1 2021[18]. - The net profit for Q1 2022 was CNY 1,158,775,246.72, a significant increase from CNY 414,970,065.30 in Q1 2021, representing a growth of approximately 178.5%[19]. - Operating profit for Q1 2022 reached CNY 1,359,112,502.61, compared to CNY 497,242,044.83 in the same period last year, indicating a year-over-year increase of about 173%[19]. Assets and Liabilities - The total assets at the end of the reporting period were RMB 22,373,434,883.94, a 6.64% increase from RMB 20,921,200,513.89 at the end of the previous year[4]. - Total assets increased to ¥22,373,434,883.94 from ¥20,979,450,562.75, reflecting a growth of 6.6%[18]. - Total liabilities amounted to ¥10,531,409,090.49, up from ¥10,306,761,328.24, indicating an increase of 2.2%[18]. - The company's total liabilities as of March 31, 2022, were CNY 6,964,728,562.82, compared to CNY 6,711,319,376.80 at the end of 2021, an increase of 3.8%[26]. Shareholder Equity and Stock Repurchase - Shareholders' equity attributable to the parent company increased to RMB 11,842,025,793.45, reflecting a 10.96% rise from RMB 10,621,533,338.75 at the end of the previous year[4]. - As of September 28, 2021, the company completed its share repurchase plan, having repurchased 34.22 million shares, accounting for 1.10% of the total share capital[12]. - The total amount spent on the share repurchase was RMB 200.48 million[12]. - The company has repurchased a total of 17.1621 million shares as of the latest announcement, which is 0.55% of the total share capital, with a total expenditure of RMB 120.186 million[13]. - The company plans to cancel 30.0696 million shares from the repurchased stock, reducing its registered capital[12]. - The company’s major shareholders include Meng Qingshan with 854.1 million shares and Chen Zhan with 102.5 million shares[10]. - The company’s stock repurchase plan is in compliance with the regulations of the Shanghai Stock Exchange[13]. Cash Flow and Investment Activities - The cash flow from operating activities for Q1 2022 was CNY 728,205,947.13, a turnaround from a negative cash flow of CNY -348,842,872.03 in Q1 2021[22]. - The total cash outflow from investing activities in Q1 2022 was CNY 974,154,775.39, compared to CNY 578,499,320.80 in Q1 2021, indicating increased investment efforts[22]. - Cash inflow from operating activities totaled CNY 5,090,100,956.01, compared to CNY 3,260,896,894.61 in the same period last year, indicating a year-over-year increase of about 56.1%[31]. - The net cash flow from financing activities was CNY 449,375,431.24, compared to CNY 12,878,677.96 in the same quarter last year, showing a significant increase[32]. Research and Development - Research and development expenses for Q1 2022 were CNY 59,037,845.21, slightly up from CNY 58,177,873.82 in Q1 2021, indicating a focus on innovation[19].